Wang Zheng, Zhang Chao, Jing Taile, Wei Yong, Xiao Chengwu, Wang Yang, Fang Yu, Wu Xiaofeng, Tang Shouyan, Xu Hong, Liu Yi, Yang Bo, Wang Shuo, Xu Bin, Zhu Qingyi, Xia Dan, Wu Zhenjie, Gao Xiaofeng, Wang Linhui
Department of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Department of Urology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Asian J Urol. 2025 Apr;12(2):152-161. doi: 10.1016/j.ajur.2024.07.002. Epub 2024 Jul 26.
This study aimed to assess the feasibility and safety of the SHURUI single-port robotic surgical system for a range of major urological surgeries.
In this prospective, multicenter clinical trial, we examined the effectiveness of the SHURUI single-port robotic surgical system in urological interventions. The first 50 patients from four centers in China underwent single-port surgeries including partial nephrectomy, radical prostatectomy, partial adrenalectomy, and pyeloureteroplasty, exclusively by the SHURUI single-port robotic surgical system. The study's primary endpoints focused on the success of surgeries, defined as no deviations from planned procedures, no need for more than one port, and no re-operations within 24 h after surgery. Secondary endpoints encompassed a range of surgical metrics, functional outcomes, and patient demographic data. Clinical assessments were conducted before surgery, before discharge, and 1 month after discharge.
The surgical procedures were executed successfully without requiring intraoperative conversions or transfusions. Both estimated blood loss and operation durations were maintained within satisfactory limits. For each type of surgery, the mean console times and estimated blood loss were 179.8 (standard deviation [SD] 39.4) min and 125.6 (SD 126.0) mL for radical prostatectomy, 126.7 (SD 47.8) min and 39.2 (SD 54.4) mL for partial nephrectomy, 112.6 (SD 37.4) min and 20.0 (SD 13.2) mL for partial adrenalectomy, and 148.0 (SD 18.2) min and 18.0 (SD 17.9) mL for pyeloureteroplasty, respectively. Across the cohort, 17 patients experienced a total of 25 adverse events, while 10 postoperative complications, all rated as Clavien-Dindo grade I, were encountered by eight patients. All patients had shown recovery or improvement from these events before the end of this trial.
The SHURUI single-port robotic surgical system demonstrated feasibility and safety in the performance of major urological surgeries. These initial findings highlight the system's potential, though further research and longer follow-up are required to assess long-term outcomes.
本研究旨在评估舒瑞单孔机器人手术系统用于一系列主要泌尿外科手术的可行性和安全性。
在这项前瞻性多中心临床试验中,我们考察了舒瑞单孔机器人手术系统在泌尿外科干预中的有效性。来自中国四个中心的首批50例患者仅通过舒瑞单孔机器人手术系统接受了包括部分肾切除术、前列腺癌根治术、部分肾上腺切除术和肾盂输尿管成形术在内的单孔手术。该研究的主要终点集中在手术的成功,定义为无偏离计划手术、无需超过一个手术切口且术后24小时内无需再次手术。次要终点包括一系列手术指标、功能结局和患者人口统计学数据。在手术前、出院前和出院后1个月进行临床评估。
手术过程顺利完成,无需术中转换或输血。估计失血量和手术时间均保持在满意范围内。对于每种类型的手术,前列腺癌根治术的平均控制台操作时间和估计失血量分别为179.8(标准差[SD]39.4)分钟和125.6(SD 126.0)毫升,部分肾切除术为126.7(SD 47.8)分钟和39.2(SD 54.4)毫升,部分肾上腺切除术为112.6(SD 37.4)分钟和20.0(SD 13.2)毫升,肾盂输尿管成形术为148.0(SD 18.2)分钟和18.0(SD 17.9)毫升。在整个队列中,17例患者共经历了25次不良事件,8例患者出现了10例术后并发症,均评为Clavien-Dindo I级。所有患者在本试验结束前均已从这些事件中恢复或有所改善。
舒瑞单孔机器人手术系统在主要泌尿外科手术中显示出可行性和安全性。这些初步发现突出了该系统的潜力,不过需要进一步研究和更长时间的随访来评估长期结局。